APG Health

We are now Risk Evaluation and Mitigation Strategy (REMS) certified to provide SPRAVATO™ (esketamine) CIII, a nasal spray approved for use in conjunction with an oral antidepressant in adults with treatment-resistant depression (TRD).¹ People who are currently struggling with major depressive disorder (MDD) may have TRD if they have not responded adequately to at least two different antidepressants of adequate dose and duration in the current depressive episode.²

As a certified treatment center, our medical staff have been trained to prescribe, dispense and administer SPRAVATO™and have established processes and procedures in accordance with the REMS. A healthcare provider will provide direct supervision as the patient self-administers SPRAVATO™ and will monitor every patient after every dose for at least two hours for resolution of sedation and dissociation and changes in vital signs. SPRAVATO™ must never be dispensed directly to a patient for home use.

Additionally, all patients will require transportation from APG Healthcare following the observation period,as they should not drive or operate machinery until the day after a treatment session, following a restful sleep.

For more information regarding administration, REMS requirements, or other related questions, please contact one of our administrative assistants at 407-423-7149.

Because of the risks for sedation, dissociation(feeling disconnected from yourself, your thoughts, feelings, space and time),and abuse and misuse, SPRAVATO™ carries a Boxed WARNING and is only available through a restricted program called the SPRAVATO™ Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO™ can only be administered at healthcare settings certified in the SPRAVATO™ REMS Program and to patients enrolled in the program.

For more information on SPRAVATO™, please refer to the manufacturer’s Prescribing Information and Medication Guide or visit www.SPRAVATO.com. If you are a patient, please speak to your healthcare provider for more information.